Ami Shah is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5501 Hopkins Bayview Cir
Room 1b32
Baltimore, MD 212246821
Telephone
410-550-7715Registry record last updated 8 Jan 2013.
Clinical trials
- Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency
Sponsor: Rocket Pharmaceuticals Inc.
- Gene Therapy for Pyruvate Kinase Deficiency (PKD)
Sponsor: Rocket Pharmaceuticals Inc.
- Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation
Sponsor: Stanford University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20259 payments
- Janssen Scientific Affairs, LLCProgram year20241 payment
- AstraZeneca Pharmaceuticals LPProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
31.7%Calcium channel blocker25.7%Amlodipine Besylate100%Part D≥17 patientsBlood Viscosity Reducer5.9%Pentoxifylline100%Part D<11 patientsCancer & immunology
21.8%Kinase inhibitor9.4%Ofev100%Part D<11 patientsFolate Analog Metabolic Inhibitor6.9%Methotrexate100%Part D<11 patients+ 1 more class in this area
Antiparasitic
21.8%Antimalarial21.8%Hydroxychloroquine Sulfate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- Autoantibodies define scleroderma subgroups with distinct relationships to cancer
Johns Hopkins University
FY2026$661,037R01AR073208 - Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma
Johns Hopkins University
FY2026$169,411K24AR080217 - Autoantibodies define scleroderma subgroups with distinct relationships to cancer
Johns Hopkins University
FY2025$635,462R01AR073208
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”